Index of 2004 Publications
2:
Subramanian S, West RB, Corless CL, Ou W, Rubin BP,
Chu KM, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard
T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR,
Heinrich MC, Fletcher JA, Van De Rijn M. Gastrointestinal
stromal tumors (GISTs) with KIT and PDGFRA mutations
have distinct gene expression profiles. Oncogene.
2004 Aug 23
PMID:
15326474
Download
PDF
3:
Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich
MC, Reimer CL, Druker BJ, Deininger MW. Sensitivity
of oncogenic KIT mutants to the kinase inhibitors
MLN518 and PD180970. Blood. 2004 Aug 10
PMID:
15304388
Download
PDF
6:
Borg C, Terme M, Taieb J, Menard C, Flament C, Robert
C, Maruyama K, Wakasugi H, Angevin E, Thielemans K,
Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crepineau
F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay
JY, Spatz A, Emile JF, Heinrich MC, Mecheri S, Tursz
T, Zitvogel L. Novel mode of
action of c-kit tyrosine kinase inhibitors leading
to NK cell-dependent antitumor effects. J Clin
Invest. 2004 Aug;114(3):379-88.
PMID: 15286804
Download
PDF
7:
Griswold IJ, Shen LJ, LaRosee P, Demehri S, Heinrich
MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker
BJ, Deininger MW. Effects of
MLN518, A Dual FLT3 and KIT Inhibitor, on Normal and
Malignant Hematopoiesis.
Blood. 2004 Jul 8
PMID:
15242881
Download
PDF
8:
Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira
AM, Heinrich MC, Fletcher JA, Fletcher CD. KIT-negative
gastrointestinal stromal tumors: proof of concept
and therapeutic implications. Am J Surg Pathol.
2004 Jul;28(7):889-94.
PMID:
15223958
Download
PDF
9:
Heinrich MC, Corless CL. Targeting
mutant kinases in gastrointestinal stromal tumors:
a paradigm for
molecular therapy of other sarcomas. Cancer
Treat Res. 2004;120:129-50. Review.
PMID:
15217222
PDF Not Available
10:
West RB, Corless CL, Chen X, Rubin BP, Subramanian
S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel
R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn
M. The novel marker, DOG1, is
expressed ubiquitously in gastrointestinal stromal
tumors irrespective of KIT or PDGFRA mutation status.
Am J Pathol. 2004 Jul;165(1):107-13.
PMID:
15215166
Download
PDF
11:
Bono P, Krause A, von Mehren M, Heinrich MC, Blanke
CD, Dimitrijevic S, Demetri GD, Joensuu H. Serum
KIT and KIT ligand levels in patients with gastrointestinal
stromal tumors treated with imatinib. Blood.
2004 Apr 15;103(8):2929-35. Epub 2004 Jan 08.
PMID:
15070666
Download
PDF
12:
Duensing A, Heinrich MC, Fletcher CD, Fletcher JA.
Biology of gastrointestinal
stromal tumors: KIT mutations and beyond. Cancer
Invest. 2004;22(1):106-16. Review.
PMID:
15069768
PDF Not Available
13:
Heinrich MC. Targeting FLT3
kinase in acute myelogenous leukemia: progress, perils,
and prospects. Mini Rev Med Chem. 2004 Mar;4(3):255-71.
Review.
PMID:
15032673
Download
PDF
14:
Hayes-Lattin B, Seipel TJ, Gatter K, Heinrich MC,
Maziarz RT. Pure red cell aplasia
associated with parvovirus B19 infection occurring
late
after allogeneic bone marrow transplantation.
Am J Hematol. 2004 Mar;75(3):142-5.
PMID:
14978694
Download
PDF
15:
Deininger MW, McGreevey L, Willis S, Bainbridge TM,
Druker BJ, Heinrich MC. Detection
of ABL kinase domain mutations with denaturing high-performance
liquid chromatography. Leukemia. 2004 Apr;18(4):864-71.
PMID:
14973502
Download
PDF
16:
Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller
M, Muller C, Niederwieser D, Druker BJ, Deininger
MW. High incidence of BCR-ABL
kinase domain mutations and absence of mutations of
the PDGFR and KIT activation loops in CML patients
with secondary resistance to imatinib. 17:
Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley
A, Griffith D, Cummings OW, Wait C, Town A, Heinrich
MC. KIT mutations are common
in testicular seminomas. Am J Pathol. 2004
Jan;164(1):305-13.
Hematol J. 2004;5(1):55-60.
PMID:
14745431
PMID:
14695343
Download
PDF